Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections

In Vivo Comparison of the Pharmacodynamic Targets for Echinocandin Drugs against Candida Species

(2010) D. Andes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest Methods with the CLSI Broth Microdilution Method for Echinocandin Susceptibility Testing of Candida Species

(2010) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Micafungin Concentrations from Brain Tissue and Pancreatic Pseudocyst Fluid

(2009) A. Lat et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Bronchopulmonary Disposition of Intravenous Voriconazole and Anidulafungin Given in Combination to Healthy Adults

(2009) J. L. Crandon et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Echinocandin Susceptibility Testing of Candida Species: Comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, Disk Diffusion, and Agar Dilution Methods with RPMI and IsoSensitest Media

(2009) M. C. Arendrup et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Combination Therapy in Treatment of Experimental Pulmonary Aspergillosis: In Vitro and In Vivo Correlations of the Concentration- and Dose- Dependent Interactions between Anidulafungin and Voriconazole by Bliss Independence Drug Interaction Analysis

(2009) V. Petraitis et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Anidulafungin in Combination with Amphotericin B against Aspergillus fumigatus

(2009) E. Spreghini et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Combination Therapy of Advanced Invasive Pulmonary Aspergillosis in Transiently Neutropenic Rats Using Human Pharmacokinetic Equivalent Doses of Voriconazole and Anidulafungin

(2009) W. W. J. van de Sande et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3- -D-Glucan Synthase: Implication for the Existing Susceptibility Breakpoint

(2009) G. Garcia-Effron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America

(2009) Peter G. Pappas et al.   CLINICAL INFECTIOUS DISEASES

Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit

(2009) M.A. Ghannoum et al.   CLINICAL MICROBIOLOGY AND INFECTION

Utilization and dosage pattern of echinocandins for treatment of fungal infections in US hospital practice

(2009) Sheenu Chandwani et al.   CURRENT MEDICAL RESEARCH AND OPINION

Extended daily dialysis does not affect the pharmacokinetics of anidulafungin

(2009) Olaf Burkhardt et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

A Phase 2, Open-Label Study of the Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis

(2009) José A Vazquez et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Fungicidal activity of anidulafungin in serum from patients does not correlate to its susceptible breakpoint against Candida spp.

(2009) G. E. Stein et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Activity of Contemporary Antifungal Agents, Including the Novel Echinocandin Anidulafungin, Tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: Report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007)

(2009) S. A. Messer et al.   JOURNAL OF CLINICAL MICROBIOLOGY

In Vitro Susceptibility of Clinical Isolates of Aspergillus spp. to Anidulafungin, Caspofungin, and Micafungin: a Head-to-Head Comparison Using the CLSI M38-A2 Broth Microdilution Method

(2009) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Pharmacokinetics and Tissue Distribution of Anidulafungin in Rats

(2008) B. Damle et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activities of Various Antifungal Drugs against Aspergillus terreus: Global Assessment Using the Methodology of the European Committee on Antimicrobial Susceptibility Testing

(2008) C. Lass-Florl et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Susceptibility Testing of Anidulafungin and Voriconazole Alone and in Combination against Conidia and Hyphae of Aspergillus spp. under Hypoxic Conditions

(2008) S. Perkhofer et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro and In Vivo Studies To Characterize the Clearance Mechanism and Potential Cytochrome P450 Interactions of Anidulafungin

(2008) B. D. Damle et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A Naturally Occurring Proline-to-Alanine Amino Acid Change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis Accounts for Reduced Echinocandin Susceptibility

(2008) G. Garcia-Effron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Correlating Echinocandin MIC and Kinetic Inhibition of fks1 Mutant Glucan Synthases for Candida albicans: Implications for Interpretive Breakpoints

(2008) G. Garcia-Effron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Combination Echinocandin-Polyene Treatment of Murine Mucormycosis

(2008) A. S. Ibrahim et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Correlation of MIC with Outcome for Candida Species Tested against Caspofungin, Anidulafungin, and Micafungin: Analysis and Proposal for Interpretive MIC Breakpoints

(2008) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Pharmacology and Antifungal Properties of Anidulafungin, a New Echinocandin

(2008) Kristina E Estes et al.   PHARMACOTHERAPY